Key Highlights

• Vivani Medical shareholders approved an amendment to the Omnibus Incentive Plan at its most recent annual meeting.

• Holders of 62,071,530 shares, representing a substantial portion of Vivani’s 86,235,104 outstanding common shares, participated in the vote.

• The company obtained approval from an Australian ethics committee to commence a Phase 1 trial of its semaglutide implant, NPM‑139.

• No other provisions of the original plan were modified.

Vivani Medical has refreshed its compensation framework while moving forward with its clinical program focused on obesity treatment. The company secured the necessary shareholder endorsement for the plan change and cleared a pivotal regulatory step for its experimental implant.

Incentive Plan Update

The board approved a revised version of the 2022 Omnibus Incentive Plan, and the amendment required shareholder ratification. A copy of. The amendment did not alter any other terms of the original plan.

Shareholder Participation

Shareholders holding 62,071,530 shares out of a total of 86,235,104 outstanding common shares voted on the amendment, satisfying the quorum threshold and allowing the plan amendment to be adopted.

Australian Ethics Approval

Vivani announced that an Australian human research ethics panel granted permission to begin its SLIM‑1 study, a Phase 1 investigation of the semaglutide implant known as NPM‑139. The connection with this announcement.

Focus on Clinical Development

The SLIM‑1 study represents a key milestone for Vivani’s strategy to deliver a long‑acting obesity therapy. By embedding the active peptide in an implantable device, Vivani aims to provide continuous drug exposure that may enhance adherence compared with conventional injection schedules.

Market and Investor Perspective

These developments underscore Vivani’s progress on both governance and product advancement fronts. Successful outcomes from the Phase 1 study could position the company as a contender in the expanding field of metabolic disease therapeutics.

Anticipated Next Steps

With ethical clearance secured, Vivani will proceed to recruit participants and collect early safety and pharmacokinetic information. The timeline for study completion has not been disclosed, but the company plans to report interim findings as they become available.

Industry Landscape

The pursuit of innovative obesity solutions reflects a broader industry shift toward therapies that improve patient convenience and sustain therapeutic effect. Vivani’s implant approach aligns with ongoing efforts by multiple biopharmaceutical firms to differentiate their pipelines through novel delivery methods.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.